Enterprise Value
19.24M
Cash
639.4M
Avg Qtr Burn
-24.29M
Short % of Float
13.28%
Insider Ownership
6.51%
Institutional Own.
87.71%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis | Phase 3 Initiation | |
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis , Cirrhosis | Phase 2b Data readout |